Comparative Pharmacology
Head-to-head clinical analysis: AMOXIL versus BACTOCILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXIL versus BACTOCILL.
AMOXIL vs BACTOCILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
None Documented
None Documented
Terminal half-life: 1-1.5 hours (normal renal function); prolonged to 7-20 hours in anuria; neonates: 3-4 hours.
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
Renal: 60-80% unchanged via tubular secretion and glomerular filtration; Biliary/fecal: minor, <5% excreted in bile; dose adjustment in CrCl <30 mL/min.
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic